Cargando…

IDO1 is an Integral Mediator of Inflammatory Neovascularization

The immune tolerogenic effects of IDO1 (indoleamine 2,3-dioxygenase 1) have been well documented and genetic studies in mice have clearly established the significance of IDO1 in tumor promotion. Dichotomously, the primary inducer of IDO1, the inflammatory cytokine IFNγ (interferon-γ), is a key media...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mondal, Arpita, Smith, Courtney, DuHadaway, James B., Sutanto-Ward, Erika, Prendergast, George C., Bravo-Nuevo, Arturo, Muller, Alexander J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161421/ https://www.ncbi.nlm.nih.gov/pubmed/27889479 http://dx.doi.org/10.1016/j.ebiom.2016.11.013

Ejemplares similares

IDO1 and inflammatory neovascularization: bringing new blood to tumor-promoting inflammation
por: Muller, Alexander J., et al.
Publicado: (2023)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
por: Dey, Souvik, et al.
Publicado: (2020)

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan
por: Metz, Richard, et al.
Publicado: (2012)

Antimetabolite TTL-315 selectively kills glucose-deprived cancer cells and enhances responses to cytotoxic chemotherapy in preclinical models of cancer
por: DuHadaway, James, et al.
Publicado: (2016)

IDO2 in Immunomodulation and Autoimmune Disease
por: Prendergast, George C., et al.
Publicado: (2014)

RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus
por: Mandik-Nayak, Laura, et al.
Publicado: (2017)

IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity
por: Merlo, Lauren M.F., et al.
Publicado: (2016)

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models
por: Takahashi, N, et al.
Publicado: (2012)

Iminosugar Amino Acid idoBR1 Reduces Inflammatory Responses in Microglia
por: Olajide, Olumayokun A., et al.
Publicado: (2022)

Trial watch: IDO inhibitors in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2020)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
por: Duan, Zhenzhen, et al.
Publicado: (2020)

Meglumine Exerts Protective Effects against Features of Metabolic Syndrome and Type II Diabetes
por: Bravo-Nuevo, Arturo, et al.
Publicado: (2014)

Inflammatory Choroidal Neovascularization
por: Neri, Piergiorgi, et al.
Publicado: (2009)

Iminosugar idoBR1 Isolated from Cucumber Cucumis sativus Reduces Inflammatory Activity
por: Nash, Robert J., et al.
Publicado: (2020)

Genetic Polymorphisms Affecting IDO1 or IDO2 Activity Differently Associate With Aspergillosis in Humans
por: Napolioni, Valerio, et al.
Publicado: (2019)

Aging-associated increase in indoleamine 2,3-dioxygenase (IDO) activity appears to be unrelated to the transcription of the IDO1 or IDO2 genes in peripheral blood mononuclear cells
por: Marttila, Saara, et al.
Publicado: (2011)

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy
por: Huang, Yu-Hung, et al.
Publicado: (2016)

Indoleamine 2,3‐dioxygenase (IDO)‐1 and IDO‐2 activity and severe course of COVID‐19
por: Guo, Lihui, et al.
Publicado: (2022)

Heme-binding-mediated negative regulation of the tryptophan metabolic enzyme indoleamine 2,3-dioxygenase 1 (IDO1) by IDO2
por: Lee, Young-Kwan, et al.
Publicado: (2014)

CD4 responses against IDO
por: Andersen, Mads Hald
Publicado: (2012)

IDO-GCN2 and autophagy in inflammation
por: McGaha, Tracy L.
Publicado: (2015)

IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease
por: Sucher, Robert, et al.
Publicado: (2010)

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

An adverse tumor-protective effect of IDO1 inhibition
por: Kenski, Juliana C.N., et al.
Publicado: (2023)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Single-nucleotide polymorphisms and activities of indoleamine 2,3-dioxygenase isoforms, IDO1 and IDO2, in tuberculosis patients
por: Cao, Tingming, et al.
Publicado: (2022)

IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
por: Nandre, Rahul, et al.
Publicado: (2022)

Immunological Relevance of the Coevolution of IDO1 and AHR
por: Jaronen, Merja, et al.
Publicado: (2014)

Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis
por: Williams, Richard O.
Publicado: (2013)

IDO Targeting in Sarcoma: Biological and Clinical Implications
por: Nafia, Imane, et al.
Publicado: (2020)

IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
por: Huang, Yi-Shu, et al.
Publicado: (2020)

AhR-Mediated, Non-Genomic Modulation of IDO1 Function
por: Pallotta, Maria Teresa, et al.
Publicado: (2014)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

IRF3 and IRF7 mediate neovascularization via inflammatory cytokines
por: Simons, Karin H., et al.
Publicado: (2019)

Retrobulbar triamcinolone for inflammatory choroidal neovascularization in pregnancy
por: Maggio, Emilia, et al.
Publicado: (2020)

Unbalanced IDO1/IDO2 Endothelial Expression and Skewed Keynurenine Pathway in the Pathogenesis of COVID-19 and Post-COVID-19 Pneumonia
por: Chilosi, Marco, et al.
Publicado: (2022)

Reversal of IDO-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
por: Triplett, Todd A., et al.
Publicado: (2018)

The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1
por: Flick, Hollie E., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rueuc0b3lmv4peuu5t3g4gl19j